Form 4: Regulus Therapeutics Director Collier Receives Stock Grant

Director Kathryn J. Collier of Regulus Therapeutics Inc. reports the acquisition of 62,500 restricted stock units.

Summary

• Kathryn J. Collier, a director of Regulus Therapeutics Inc., filed a Form 4 disclosing a transaction.
• On April 30, 2025, Collier was granted 62,500 Restricted Stock Units (RSUs).
• These RSUs vest in equal monthly installments over 12 months from the grant date.
• Following the reported transaction, Collier beneficially owns 69,240 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and indicates confidence in the company's future, but it's not a major event that would drastically alter the company's prospects.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The vesting schedule of the RSUs suggests a continued alignment of the director's interests with the company's performance over the next 12 months.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholder value.

Comparison to Industry Standards

• Stock grants to directors are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation to incentivize their board members.
• The size of the grant is typical for a company of Regulus Therapeutics' size and market capitalization.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Regulus Therapeutics, RGLS, Restricted Stock Units, Director, Beneficial Ownership, Collier, Equity